Hyperhomocysteinemia in the neurological diseases;Iperomocisteinemia nelle malattie neurologiche

Recenti Progressi in Medicina

Volumn 95, Issue 7-8, 2004, Pages 371-375+402

  Siniscalchi, Antonio ^a  

^a Azienda Ospedaliera di Cosenza   (Italy)

Author keywords

Hyperhomocysteinemia; Neurological diseases

Indexed keywords

AMINO ACID; ANTICONVULSIVE AGENT; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHIONINE; PYRIDOXINE;

ALZHEIMER DISEASE; AMINO ACID ANALYSIS; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; EPILEPSY; GENETIC ANALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; METABOLIC REGULATION; METHYLATION; NEUROLOGIC DISEASE; PARKINSON DISEASE; PROTEIN INTAKE; REDUCTION; REMETHYLATION; REVIEW; RISK FACTOR; SULFURATION;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROVASCULAR DISORDERS; EPILEPSY; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; PARKINSON DISEASE;

EID: 3042767381     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Perri IJ. Homocysteine, hypertension and stroke. J Hum Hypertens 1999; 13: 289-93.
2. Kristensen B, Malm J, Nilsson TK et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke 1999; 30: 974-80.
3. van Beynum IM, Smeitink JA, den Heijer M, te Poele Pothoff MT, Blom HJ. Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation 1999; 99: 2070-2.
4. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 1999; 131: 352-5.
5. McCully KS, McCully S, Stacey M. The heart revolution: the B vitamin breakthrough that lowers homocysteine, cuts your risk of heart disease, and protects your health. New York: Harper Collins 1999.
6. Hermann W, Knapp JP. Hyperhomocysteinemia: a new risk factor for neurodegenerative disease. Clin Lab 2002; 48: 471-81.
7. Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, Walker-Sack I. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999; 40: 345-50.
8. Shelhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-8.
9. D'angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
10. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor disease. NEJM 1991; 324: 1149-55.
11. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-105.
12. Ma J, Stampfer MJ, Hennenkens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
13. Rozen R. Genetic modulation of homocysteinemia. Semin Thromb Hemost 2000; 26: 255-61.
14. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
15. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000; 57: 1422-8.
16. Jacques PF, Selhub J Bostom AG, Wilson PW, Rosenberg HI. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. NEJM 1999; 340: 1449-54.
17. Jacques PF, Rosenberg IH, Rogers J, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Nealth and Nutrition Examination Survey. Am J Clin Nutr 1999; 69: 482-9.
18. Stolzenberg-Solomon RZ, Miller ER, Maguire MG, Selhub J Appel LJ. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr 1999; 69: 467-75.
19. Bostom AG, Gohh RY, Tsai MY, Hopkins-Garcia MR, Bianchi LA, Jacques PF, et al. Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol 1997; 17: 1894-900.
20. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114: 473-501.
21. Hanhey J, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-13.
22. Ono H, Sakamoto A, Eguchi T, Fujita N, Nomura S, Ueda H, et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsant. Metabolism 1997; 46: 959-62.
23. Boushey CJ, Beresford SA, Ommen GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
24. Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral microangiography and microangiopathy. Lancet 1999; 353: 1586-7.
25. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperomocisteinemia in cerebral vein thrombosis. Blood 2003; 102: 1363-6.
26. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for disease: an overview. Clin Chem Lab Med 2001; 39: 666-74.
27. Coyle JT, Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorder. Science 1993; 626: 689-95.
28. Chambers JC McGregor A, Jean-Marie J. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamine C therapy. Circulation 1999; 99: 1156-60.
29. Nappo F, De Rose N, Marfella R. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281: 2113-8.
30. Ling Q, Ajjar KA. Inhibition of endothelial cell thromboresistance by homocysteina. J Nutr 2000; suppl 2: 373S-376S.
31. Dardik R, Varon D, Tamarin I. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000; 83: 338-44.
32. Virdis A, Gjiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocysteinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
33. Rowland LP. Nutritional disorders: vitamina B12 deficiency, malabsorbtion, and malnutrition. In: Rowland LP, ed. Merritt's Textbook of neurology. 9th ed. Baltimore: Williams and Wilkins 1995: 945-51.
34. Goodwin JS, Goodwin JM, Garry PJ. Hyperhomocysteinemia between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983; 249: 2917-21.
35. Riggs KM, Spiro A, Tucker KL, Rush D. Relations of vitamin B12, vitamin B6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996; 63: 306-14.
36. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. NEJM 2002; 346: 476-83.
37. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirme Alzheimer disease. Arch Neurol 1998; 55: 1449-55.
38. McCaddon A, Davis G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13: 235-9.
39. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999; 10: 12-20.
40. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998; 40: 225-7.
41. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60: 59-64.
42. Mud SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE. The natural history of homocystinuria due to cystationina beta-synthase deficiency. Am J Hum Genet 1985; 37:1-31.
43. Freed W. Selective inhibition of homocysteine-induced seizures by glutamic acid diethyl ester and other glutamate esters. Epilepsia 1985; 26: 30-6.
44. Schwarz S, Zhou G, Katki A, Rodbard D. L-homocysteate stimulates (3H)MK-801 biding to the phencyclidine recognition site and is thus an agonist for the N-methyl-D-aspartate-operated cation channel. Neuroscience 1990; 37: 193-200.
45. McIlwain H, Poll J. Interaction between adenosine generated endogenously in neocortical tissue, and homocysteine and its thiolactone. Neurochem Int 1985; 7: 103-10.
46. Kishi T, Fujita N, Eguchi T, Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997; 145: 109-12.
47. Morrel MJ. Guidelines for the care of woman with epilepsy. Neurology 1998; 51 (suppl 4): S21-S27.
48. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992; 42 (suppl 5): S32-S42.
49. Steegers-Theunissen RP, Boers GH, Blom HJ, Nijha JG, Thomas CM, Borm GF, Eskes TK. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 1995; 172: 1436-41.
50. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 1998; 316: 894-8.
51. Kruger WD, Evans AA, Wang L. Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid. Mol Genet Metab 2000; 70: 53-60.
52. Toole JF. Vitamin intervention for stroke prevention. J Neurol Sci 2002; 15: 121-4.